

Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology

Oliver A. Cornely,^{1,2} Angelika Böhme,³ Dieter Buchheidt,⁴ Hermann Einsele,⁵ Werner J. Heinz,⁵ Meinolf Karthaus,⁶ Stefan W. Krause,⁷ William Krüger,⁸ Georg Maschmeyer,⁹ Olaf Penack,¹⁰ Jörg Ritter,¹¹ Markus Ruhnke,¹² Michael Sandherr,¹³ Michal Sieniawski,¹⁴ Jörg-Janne Vehreschild,¹ Hans-Heinrich Wolf,¹⁵ and Andrew J. Ullmann¹⁶

¹Klinik I für Innere Medizin, Klinikum der Universität Köln, and ²Zentrum für Klinische Studien (01KN0706), Köln; ³Onkologikum Frankfurt am Museumsufer, Frankfurt; ⁴III. Medizinische Klinik, Universitätsklinikum Mannheim gGmbH, Mannheim; ⁵Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg; ⁶Klinik für Hämatologie und Onkologie, Klinikum Neuperlach, München; ⁷Medizinische Klinik 5, Hämatologie und Internistische Onkologie, Universitätsklinikum Erlangen, Erlangen; ⁸Medizinische Klinik C, Ernst-Moritz-Arndt-Universität, Greifswald; ⁹Medizinische Klinik Hämatologie und Onkologie, Klinikum Ernst von Bergmann, Potsdam; ¹⁰Charité, Campus Benjamin Franklin, Klinik für Hämatologie und Onkologie, Berlin; ¹¹Pädiatrische Hämatologie/Onkologie, Universitätsklinikum Münster, Münster; ¹²Charité Universitätsmedizin, Campus Charité Mitte, Medizinische Klinik und Poliklinik II, Berlin; ¹³Schwerpunktpraxis für Hämatologie und Onkologie, Weilheim, Germany; ¹⁴Haematological Sciences (CALs), Leech Building, Medical School, Newcastle upon Tyne, United Kingdom; ¹⁵Martin-Luther-Universität Halle-Wittenberg, Halle, and ¹⁶Johannes Gutenberg-Universität, III. Medizinische Klinik, Mainz, Germany

Citation: Cornely OA, Böhme A, Buchheidt D, Einsele H, Heinz WJ, Karthaus M, Krause SW, Krüger W, Maschmeyer G, Penack O, Ritter J, Ruhnke M, Sandherr M, Sieniawski M, Vehreschild J-J, Wolf H-H, and Ullmann AJ. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. *Haematologica* 2009. doi: 10.3324/haematol.11665

Online Supplementary Tables S1 to S7

Table S1. Fluconazole prophylaxis.

Author	Year	Design	Medication/daily dose per treatment arm	n=	Risk factors %	Invasive fungal infection			Mortality	
						Proven %	Probable %	Possible %	Total %	Fungal %
Chandrasekar ²⁰	1994	rd, db, pl	FLU 400 mg placebo	23	91 AL	8.6	0	0	17.4	8.6
				23	9 other hematomol	4.3	0	0	13	4.3
Goodman ¹⁶	1992	rd, db, pl	FLU 400 mg placebo	179	48 alloSCT	3	N/A	N/A	30.7	0.6
				177	52 autoSCT	16	N/A	N/A	26	5.6
Rotstein, Laverdière ^{21,31}	1999	rd, db, pl	FLU 400 mg placebo	141	50 AML	2.8	3.5	36	11	0.7
				133	10 ALL 31 other hematomol 9 solid tumor 44 autoSCT	16.5	7.5	26	11	4.5
Schaffner ²²	1995	rd, db, pl	FLU 400 mg placebo	75	72 AML	8	2.7	6.6	5.3	2.6
				76	28 NHL relapse 10 autoSCT	9.2	1.3	7.9	6.6	2.6
Slavin, Marr ^{18,19}	1995	rd, db, pl	FLU 400 mg placebo	152	20 AML	7	—	38	20	13
				148	10 ALL 55 NHL/HD 15 other 88 alloSCT 12 autoSCT	18	—	55	35	21
Winston ²³	1993	rd, db, pl	FLU 400 mg placebo	123	80 AML	4	N/A	N/A	0.8	0
				132	20 ALL	8	N/A	N/A	3	0
MacMillan ³¹	2002	rd	FLU 400 mg FLU 200 mg	124	36 AL	7.3	N/A	N/A	N/A	N/A
				129	25 CML 17 NHL/HD 22 other 56 alloSCT 44 autoSCT	2.3	N/A	N/A	N/A	N/A

continuing on next page

Ullmann ²⁹	2007	rd, db	FLU 400 mg POS 600 mg	299 301	100 alloSCT	7 2.3	2 3	28.1 25.2	4 1	
Cornely ²⁸	2007	rd	FLU 400 mg OR ITR 400 mg oral sol POS 600 mg	298 304	86 AML 14 MDS	8.4 2.3	N/A N/A	22.5 16.1	5.4 1.7	
Winston ³⁸	2003	rd	FLU 400 mg i.v./p.o. ITR d1-2: 400 mg i.v., d3-: 200 mg i.v. or 400 mg sol	67 71	100 alloSCT	25.4 8.5	N/A N/A	N/A N/A	17.9 8.5	
Glasmacher ³⁷	2006	rd	FLU 400 mg sol ITR 5 mg/kg sol	246 248	72.9 AML 12.1 ALL 15 other	2 1.6	11.4 8.9	11.4 10.1	1.2 0.8	
Marr ³⁹	2004	rd	FLU 400 mg i.v./p.o. ITR 200 mg i.v./ 7.5 mg/kg sol	148 149	100 alloSCT	16.2 12.1	N/A N/A	39.2 30.9	8 7.4	
van Burik ⁶⁹	2004	rd, db, pl	FLU 400 mg i.v. MIC 50 mg	457 425	14 AML 3 ALL 12 CML 24 NHL 20 MM 46 autoSCT 54 alloSCT	26.5 20		5.7 4.2	0.4 0.2	
Wingard ⁴⁶	2007	rd, db, abs	FLU 400 mg VCZ 400 mg		38 AML 20 ALL 17 CML 25 other 100 alloSCT	N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A	
Oren ⁹²	2006	rd	FLU 400 mg ITR 400 mg oral sol or ITR 200 mg IV	99 96	31 AML 5 ALL 23 NHL 4 HD 55 autoSCT 19 alloSCT	2 1	6 5.2	1 3.1	11.1 9.4	9.1 5.2
Mattiuzzi ³³	2003	rd	FLU 400 mg + ITR 400 mg cps L-AmB 3 mg/kg i.v. tiw	67 70	100 AML	4.5 4.3	N/A N/A	16 8.6	11.9 14.3	1.5 1.4
Yamac ⁹⁴	1995	rd	FLU 400 mg No prophylaxis	41 29	N/A	9.8 31		N/A N/A	N/A N/A	
Bodey ⁷⁰	1994	rd	FLU 400 mg AmB 0.5 mg/kg tiw i.v.	41 36	94 AML 6 ALL	4.8 8.3	7.3 19.4	4.8 2.7	14.6 25	0 2.7
Egger ⁶⁰	1995	rd	FLU 400 mg p.o./i.v. NYS 72 Mill IU + MCZ inh. (dose N/A)	43 46	46 AL 16 NHL/HD 38 other	2.3 4.3		N/A N/A	2.3 0	
Kern ⁹⁵	1998	rd	FLU 400 mg + AmB 240 mg AmB 240 mg	36 32	100 AML-Rez.	5.6 6.3	0 0	53 34	22 19	0 0
Wolff ⁶⁹	2000	rd	FLU 400 mg AmB 0.2 mg/kg i.v.	196 159	103 alloSCT 252 autoSCT	4.1 7.5	N/A N/A	N/A N/A	12.2 11.9	2.6 1.3
Hashino ⁹⁶	2008	hist contr	FLU 400 p.o. OR i.v. MIC 100 mg	29 44	27 AML 19 ALL 54% other 100% alloSCT	6.9 0	3.4 0	24.1 11.4	10.3 9.1	6.9 0
Annaloro ⁹⁷	1995	rd, hist contr	FLU 300 mg + NYS (dose N/A) FLU 50 mg + NYS (dose N/A) ITR 400 mg cps + NYS (dose N/A)	28 30 31	35 alloSCT 65 autoSCT	3.6 3.3 12.9	7.1 6.6 3.2	7.1 3.3 6.4	0 0 0	
Ito ⁹⁸	2007	rd	FLU 200 mg ITR 200 mg cps	110 108	100 AML/MDS	0 0	7.3 0	2.7 3.7	N/A N/A	N/A N/A
Akayima ⁹⁹	1993	rd	FLU 200 mg AmB 2.4 g	71 59	80 AML 18 ALL 2 NHL	1.4 3.4	N/A N/A	N/A N/A	N/A N/A	N/A N/A
Young ²⁴	1999	rd, db, pl	FLU 200 mg NYS 6 Mill IU	86 78	68 AML 25 ALL 7 other	4.7 7.7	N/A N/A	16 24	7 14	2 4

continuing on next page

Ellis ⁶¹	1994	rd	FLU 200 mg CLO 20 mg + NYS 2 Mill IU	42 48	47 AML 30 ALL 8 NHL/HD 16 other 26 alloSCT	4.8 21	2.3 2.1	N/A N/A	N/A N/A	4.8 18.8
Meunier ¹⁰⁰	1991	hist contr	FLU 200 mg AmB 430 mg	30 29	68 AL 22 NHL/HD 10 other	13.3 17.2	N/A N/A	N/A N/A	16.7 27.6	3.3 10.3
Timmers ⁸⁴	2000	rd	FLU 200 mg ABCD 2 mg/kg i.v.	12 12	25 AML 8 ALL 67 other haematol	0 0	N/A N/A	N/A N/A	0 17	0 0
Takatsuka ¹⁰¹	1999	hist contr	FLU 200 mg + AmB sol 300 mg + AmB inh. (dose N/A) AmB 300 mg + AmB sol 300 mg + AmB inh. (dose N/A)	54 70	46 AML 18 ALL 19 NHL 5 CML	0 7	N/A N/A	N/A N/A	N/A N/A	N/A N/A
Ninane ¹⁰²	1994	rd	FLU 3 mg/kg NYS 0.2 Mill IU/kg +/- AmB 100 mg/kg	245 257	53 AL 12 NHL/HD 30 solid tumor 5 other	0.8 1.9	N/A N/A	N/A N/A	1.2 2.3	N/A
Groll ¹⁰³	1997	rd	FLU 3 mg/kg NYS 50.000 IU/kg	25 25	N/A	4 0	4 8	N/A N/A	N/A N/A	N/A N/A
Alangaden ¹⁰⁴	1994	hist contr	FLU 100/200 mg no prophylaxis	112 79	50 AL 36 NHL/HD 15 other 67 alloSCT 33 autoSCT	3.6 10.1	N/A N/A	N/A N/A	8.9 17.7	0.9 3.8
Menichetti ²⁵	1994	rd	FLU 150 mg AmB 2g sol	420 400	81 AML 19 ALL	2.6 2.5	N/A N/A	16 21	10.5 10	1.2 0.8
Huijgens ²⁷	1999	rd, db	FLU 100 mg ITR 200 mg cps	101 101	39 AL 61 other haematol	4 4	7 4	1 2	7 11	3 6
Morgenstern ²⁶	1999	rd	FLU 100 mg ITR 5 mg/kg sol	293 288	53 AML 12 ALL 35 other haematol	2 0.3	2.4 3.1	N/A N/A	N/A N/A	2.4 0
Philpott-Howard, 1993 Brammer, Rozenberg-Arska ^{17,62,105}		rd	FLU 50 mg AmB 2g sol or NYS 4 Mill IU	256 255	76 AL 22 other haematol 2 solid tumor 21 alloSCT	2.4 3.5	N/A N/A	N/A N/A	N/A N/A	N/A N/A
Finke ¹⁰⁶	1990	rd	FLU 50 mg AmB 800 mg	19 21	N/A	N/A N/A	N/A N/A	N/A N/A	15.8 9.5	N/A N/A

Medication given p.o. and dosing interval qd unless otherwise stated, abs = abstract, ABCD: amphotericin B colloidal dispersion; AmB: amphotericin B; CAS: caspofungin; CLO: clotrimazole; db = double blind, FLU = fluconazole; HEPA: high-efficiency particulate air filters, hist contr = historical control group, inh. = inhalation, ITR = itraconazole, LAF = laminar air-flow, N/A = data not available, KTC: ketoconazole; MCZ = miconazole, MIC = micafungin; sol = oral solution, NYS = nystatin, pl = placebo controlled, rd = randomised, tiw denotes thrice weekly.

Table S2. Itraconazole prophylaxis.

Author	Year	Design	Medication/daily dose per treatment arm	n=	Risk factors %	Invasive fungal infection			Mortality	
						Proven %	Probable %	Possible %	Total %	Fungal %
Winston ³⁸	2003	rd	ITR d1-2: 400 mg i.v., d3-: 200 mg i.v. or 400 mg sol FLU 400 mg i.v./p.o.	71	100 alloSCT	8.5	N/A	N/A	N/A	8.5
				67		25.4	N/A	N/A	N/A	17.9
Mattiuzzi ⁸⁷	2006	rd	ITR 400 mg i.v. (d1-2), 200 mg i.v. (d3-) CAS 50 mg	90	75 AML	5.5	N/A	N/A	7.8	2.2
				107	25 MDS	6.5	N/A	N/A	6.5	3.7
Oren ⁹²	2006	rd	ITR 400 mg oral sol or ITR 200 mg IV FLU 400 mg	96	31 AML, 5 ALL	1	5.2	3.1	9.4	5.2
				99	23 NHL, 4 HD 55 autoSCT, 19 alloSCT	2	6	1	11.1	9.1
Marr ³⁹	2004	rd	ITR 200 mg i.v./ 7.5 mg/kg sol FLU 400 mg i.v./p.o.	149	100 alloSCT	12.1	N/A	N/A	30.9	7.4
				148		16.2	N/A	N/A	39.2	8.0
Cornely ²⁸	2007	rd	FLU 400 mg OR ITR 400 mg oral sol POS 600 mg	298	86 AML	8.4	N/A	N/A	22.5	5.4
				304	14 MDS	2.3	N/A	N/A	16.1	1.7
Lass-Flörl ¹⁰⁷	2003	rd	ITR 10 mg/kg sol AmB 3g	56	49 AML, 29 ALL	1.8	5.4	5.4	5.4	0
				59	22 other	6.8	5.1	5.1	5.1	3.4
Böhme ⁷²	2000	hist contr	ITR 400 mg sol AmB 0.5 mg/kg/tiw i.v.	72	87 AML, 9 ALL	16.7	8.3	4.1	N/A	N/A
				61	4 other	0	9.3	1.6	N/A	N/A
Harousseau ¹⁰⁸	2000	rd, db, pl	ITR 5 mg/kg sol AmB 2 g cps	281	57 AML, 13 ALL	2.8	30	6	6	0.4
				276	29 other	4.7	29	8	8	1.8
Menichetti ³⁵	1999	rd, db, pl	ITR 5 mg sol + NYS 2 Mill. IU placebo + NYS 2 Mill. IU	201	76 AL	2.5	21	7.5	7.5	0.5
				204	24 other	4.4	29	8.8	8.8	2.5
Glasmacher ³⁷	2006	Rd	ITR 5 mg/kg sol FLU 400 mg sol	248	72.9 AML	1.6	8.9	10.1	10.1	0.8
				246	12.1 ALL, 15 other	2	11.4	11.4	11.4	1.2
Morgenstern ²⁶	1999	rd	ITR 5 mg/kg sol FLU 100 mg	288	53 AML, 12 ALL	0.3	3.1	N/A	N/A	0
				293	35 other	2	2.4	2.4	2.4	2.4*
Boogaerts ³⁶	2001	rd	ITR 200 mg sol AmB 1.5 g + NYS 2 Mill IU	144	66 AML	4.9	2.8	11.8	11.8	4.2
				133	9 SCT	5.3	3.8	12.8	12.8	4.5
Glasmacher ⁴²	1998	hist contr	ITR 400/600 mg cps + AmB Sol 2.4 g or NYS 24 Mill. IU AmB 2.4g sol or NYS 24 Mill. IU	47	~85 AML	N/A	N/A	N/A	17.9	0.9
				76	~15 ALL ~22 AL relapse	N/A	N/A	N/A	25	8.8
Mattiuzzi ³³	2003	rd	ITR 400 mg cps + FLU 400 mg L-AmB 3 mg/kg i.v. tiw	67	100 AML	4.5	N/A	16	11.9	1.5
				70		4.3	N/A	8.6	14.3	1.4
Kaptan ¹⁰⁹	2003	rd	ITR 400 mg cps no prophylaxis	31	56 AML	6.5	6.5	N/A	16.1	0
				24	44 ALL	8.3	16.7	N/A	8.3	0
Vreugdenhil ¹¹⁰	1993	rd, db, pl	ITR 400 mg cps + AmB 4 g sol placebo + AmB 4g sol	46	64 AML	10.9	4.3	6.5	21.7	15.2
				46	24 ALL, 12 other	19.6	2.2	10.9	30.4	15.2
Annaloro ⁹⁷	1995	rd, hist contr	ITR 400 mg cps + NYS (dose N/A) FLU 300 mg + NYS (dose N/A) FLU 50 mg + NYS (dose N/A)	31	35 alloSCT	12.9	3.2	6.4	6.4	0
				28	65 autoSCT	3.6	7.1	7.1	7.1	0
				30		3.3	6.6	3.3	3.3	0
Böhme ¹¹¹	1996	hist contr	ITR 400 mg cps AmB 0.8 g p.o.	241	65 AML, 12 ALL	4.6	0.5	1.5	N/A	N/A
				223	23 other	5.4	0.9	1.3	N/A	N/A
Thunnissen ¹¹²	1991	hist contr	ITR 400 mg cps NYS 10 Mill IU	47	75 AML	0	N/A	N/A	8.5	0
				47	25 ALL/NHL	9	N/A	N/A	26	13
Tricot ¹¹³	1987	hist contr	ITR 400 mg cps KTC 400 mg	45	68 AML	24	5.5	N/A	24	15.5
				52	26 ALL 6 other	44.5	8.5	N/A	40.5	36.5
Lamy ¹¹⁴	1998	non-comparative	ITR 400 mg cps + LAF	96	45 AML 10 ALL 45 other	2	3	N/A	N/A	0
Nucci ³³	2000	rd, db, pl	ITR 200 mg cps placebo	104	60 AML	4.8	N/A	N/A	7.7	1.9
				106	20 ALL 20 other	8.5	N/A	N/A	6.6	0.9
Huijgens ²⁷	1999	rd, db	ITR 200 mg cps FLU 100 mg	101	39 AL	4	4	2	11	6
				101	61 other	4	7	1	7	3
Ito ⁹⁸	2007	rd	ITR 200 mg cps FLU 200 mg	108	100 AML/MDS	0	0	3.7	N/A	N/A
				110		0	7.3	2.7	N/A	N/A
Todeschini ¹¹⁵	1993	hist contr	ITR 200 mg cps + AmB intranasal 10 mg no prophylaxis	164	31 AML 13 ALL	2.4	4.9	N/A	N/A	1.2
				290	41 NHL/HD 15 other 6 autoSCT	6.6	7.6	N/A	N/A	3.8

For abbreviations refer to Table S1.

Table S3. Posaconazole and voriconazole prophylaxis.

Author	Year	Design	Medication/daily dose per treatment arm	n=	Risk factors %	Invasive fungal infection			Mortality	
						Proven %	Probable %	Possible %	Total %	Fungal %
Cornely ²⁸	2007	rd	POS 600 mg FLU 400 mg OR ITR 400 mg oral sol	304	86 AML	2.3	—	N/A	16.1	1.7
				298	14 MDS	8.4	—	N/A	22.5	5.4
Ullmann ²⁹	2007	rd, db	POS 600 mg FLU 400 mg	301	100 alloSCT	2.3	—	3	25.2	1
				299		7	—	2	28.1	4
Vehreschild ¹¹⁶	2007	rd, db, pl	VCZ 400 mg placebo	10	100 AML	0	0	0	0	0
				15		0	26.7	33	13.3	0
Wingard ⁴⁶	2007	rd, db, abs	VCZ 400 mg FLU 400 mg		38 AML	N/A	N/A	N/A	N/A	N/A
					20 ALL	N/A	N/A	N/A	N/A	N/A
					17 CML	N/A	N/A	N/A	N/A	N/A
					25 other	N/A	N/A	N/A	N/A	N/A
					100 alloSCT	N/A	N/A	N/A	N/A	N/A

For abbreviations refer to Table S1.

Table S4. Ketoconazole, miconazole and clotrimazole prophylaxis.

Author	Year	Design	Medication/daily dose per treatment arm	n=	Risk factors %	Invasive fungal infection			Mortality	
						Proven %	Probable %	Possible %	Total %	Fungal %
Brincker ⁹⁰	1983	rd, db, pl	KTC 400 mg placebo	19	100 AL	10.5	N/A	N/A	N/A	N/A
				19		10.5	N/A	N/A	N/A	N/A
Hansen ⁵⁴	1987	rd, db, pl	KTC 400 mg placebo	27	59 AL	N/A	N/A	N/A	N/A	N/A
				29	9 NHL/HD	N/A	N/A	N/A	N/A	N/A
					13 autoSCT 21 other	N/A	N/A	N/A	N/A	N/A
Donnelly ⁶¹	1984	rd	KTC 400 mg AmB tab 400 mg and 70 mg loz KTC 400 mg + AmB tab 400 mg + 70 mg loz	17	94 AL	5.9	N/A	23.5	5.9	5.9
				19	6 alloBMT	5.3	N/A	10.5	5.3	5.3
				12		0	N/A	25.0	0	0
Shepp ⁵⁶	1985	rd	KTC 400 mg NYS 3 Mill IU	27	96 alloBMT	0	N/A	N/A	7.4	0
				29	4 autoSCT	6.9	N/A	N/A	17.2	6.9
Tricot ¹¹³	1987	hist contr	KTC 400 mg ITR 400 mg cps	52	68 AML	44.5	8.5	N/A	40.5	36.5
				45	26 ALL 6 other	24	5.5	N/A	24	15.5
Vogler ⁶⁷	1987	rd	KTC 400 mg NYS 2 Mill IU	22	89 AL	22.7	—	22.7	N/A	N/A
				24		33.3	—	16.7		
Estey ⁶²	1984	rd	TMP 320 mg + SMX 1.6 g KTC 400 mg KTC 400 mg + TMP 320 mg + SMX 1.6 g no prophylaxis	32	N/A	15.6	N/A	N/A	21.9	16
				32		0	N/A	N/A	21.9	0
				45		11.1	N/A	N/A	13.3	6.7
				38		2.6	N/A	N/A	15.8	0
Hann ⁵³	1982	rd	KTC 200/400 mg AmB 40 mg loz + NYS 1 Mill IU	37	83 AL	0	N/A	8.1	10.8	0
				35	17 other	5.7	N/A	5.7	25.7	5.7
Jones ⁵⁵	1984	rd	KTC 200 mg NYS 2 Mill IU	18	72 AL	5.5	N/A	N/A	N/A	N/A
				18	28 NHL/HD	0	N/A	N/A	N/A	N/A
Palmbad ⁵⁸	1992	rd, db, pl	KTC 200 mg placebo	50	100 AL	6	N/A	N/A	N/A	6
				57		1.8	N/A	N/A	N/A	0
Brincker ⁹⁹	1978	rd, db, pl	MCZ 2 g p.o. placebo	15	100 AL	6.7	N/A	N/A	N/A	N/A
				15		13.3	N/A	N/A	N/A	N/A
Egger ⁶⁰	1995	rd	NYS 72 Mill IU + MCZ inh. (dose N/A) FLU 400 mg p.o./i.v.	46	46 AL	—	4.3	—	N/A	0
				43	16 NHL/HD 38 other	—	2.3	—	N/A	2.3
Ellis ⁶¹	1994	Rd	CLO 20 mg + NYS 2 Mill IU FLU 200 mg	48	77 AL	21	2.1	N/A	N/A	18.8
				42	8 NHL/HD 16 other 26 alloSCT	4.8	2.3	N/A	N/A	4.8

For abbreviations refer to Table S1.

Table S5. Prophylaxis with systemic amphotericin B deoxycholate and lipid-based formulations.

Author	Year	Design	Medication /daily dose per treatment arm	n=	Risk factors %	Invasive fungal infection			Mortality	
						Proven%	Probable%	Possible%	Total %	Fungal %
Karthaus, Doellmann ^{71,116}	1999	hist contr	AmB 1 mg/kg/48h i.v. no prophylaxis	104	100 ALL	0	18.3	12.5	N/A	N/A
				104		4.8	34.6	19.2	N/A	N/A
Bodey ⁷⁰	1994	rd	AmB 0.5 mg/kg i.v. tiw FLU 400 mg	36	94 AML	8.3	19.4	2.7	25	2.7
				41	6 ALL	4.8	7.3	4.8	14.6	0
Böhme ⁷²	2000	hist contr	AmB 0.5 mg/kg i.v. tiw ITR 400 mg sol	61	87 AML	0	9.3	1.6	N/A	N/A
				72	9 ALL	16.7	8.3	4.1	N/A	N/A
					4 other					
Rousey ¹¹⁷	1991	hist contr	AmB 20 mg i.v. + LAF LAF no prophylaxis	110	100 alloSCT	9	N/A	N/A	20	6
				48		23	N/A	N/A	35	13
				28		25	N/A	N/A	46	18
Wolff ⁶⁹	2000	rd	AmB 0.2 mg/kg/d i.v. FLU 400 mg	159	103 alloSCT	7.5	N/A	N/A	11.9	1.3
				196	252 autoSCT	4.1	N/A	N/A	12.2	2.6
Riley ¹¹⁸	1994	rd, db, pl	AmB 0.1 mg/kg i.v. + LAF 82% placebo + LAF 44%	17	86 haematol	0	N/A	29	0	0
				18	14 solid tumor 69 alloSCT	28	N/A	44	22	11
Perfect ⁶⁸	1992	rd, bl, pl	AmB 0.1 mg/kg i.v. + HEPA placebo + HEPA	91	100 autoSCT	1.1%	N/A	N/A	3.3	0
				91	4 haematol	9.9%	N/A	N/A	12.1	2.2
					96 solid tumor					
Mattiuzzi ³³	2003	rd	L-AmB 3 mg/kg i.v. tiw FLU 400 mg + ITR cps 400 mg	70	100 AML	4.3	N/A	8.6	14.3	1.4
				67		4.5	N/A	16	11.9	1.5
Kelsey ⁶¹	1999	rd, db, pl	L-AmB 2 mg/kg i.v. tiw placebo	74	27 AML	0	— 28.3 —		15	2.7
				87	12 ALL	2.3	— 35.6 —		14	2.3
					34 CML					
					22 NHL/HD					
					5 other 53 alloSCT 31 autoSCT					
Tollema ^{76,79}	1993	rd, db, pl	L-AmB 1.0 mg/kg i.v. placebo	36	25 AML	3	— 14 —		44	3
				40	22 ALL	8	— 18 —		36	8
					42 other					
					5 solid tumor 83 alloSCT					
Penack ⁶²	2006	rd	L-AmB 50 mg q48h no prophylaxis	75	65 AML	— 6.7 —	N/A	5.3	2.7	
				57	14 ALL	— 35.1 —	N/A	14	12.3	
					20 NHL					
Cordonnier ⁶³	2008	non- comparative	L-AmB 10 mg/kg qwk	29	69 AML 17 ALL 28 alloSCT	3.4	10.3	N/A	13.8	3.4
El-Cheikh ¹¹⁹	2007	non- comparative	L-AmB 7.5 mg/kg qwk	21	100 alloSCT	N/A	— 4.8 —	38.1	0	
Timmers ⁶⁴	2000	rd	ABCD 2 mg/kg i.v. FLU 200 mg	12	25 AML	0	N/A	N/A	17	0
				12	8 ALL 67 other haematol	0	N/A	N/A	0	0

For abbreviations refer to Table S1.

Table S6. Prophylactic amphotericin B Inhalation.

Author	Year	Design	Medication/daily dose per treatment arm	n=	Risk factors %	Invasive fungal infection			Mortality	
						Proven %	Probable %	Possible %	Total %	Fungal %
Rijnders	2006	rd, db, pl	L-AmB 12.5 mg inh. + FLU (dose N/A)	139	49 AML/MDS	4.3	N/A	N/A	2.9*	3.6**
			placebo inh. + FLU (dose N/A)	132	21 autoSCT					
Alexander ⁶⁶	2006	non-comparative	ABLc 50 mg inh. d1-4, then qwk + FLU p.o./i.v. d1-100	40	100 alloSCT	7.5	0	0%	30	2.5
Erjavec ⁶⁴	1997	non-comparative	AmB 30 mg inh.	42	52 AML 41 ALL 7 other haematol	14	14	N/A	N/A	7.1
Schwartz ⁶⁵	1999	rd	AmB 20 mg inh. no prophylaxis	227	74 AML	1.8	2.2	0.4	13	8
				155	9 ALL/NHL relapse 17 autoSCT	0.6	5.8	0.6	10	7
Hertenstein ⁶³	1994	non-comparative	AmB 20 mg inh.	303	55 AML 26 CML 19 other 89 alloSCT 9 autoSCT	3.6	N/A	N/A	20.5	2.6
Takatsuka ¹⁰¹	1999	hist contr	AmB 300 mg + AmB sol 300 mg + inh. (dose N/A)	70	46 AML 18 ALL	7	N/A	N/A	N/A	N/A
			FLU 200 mg + AmB sol 300 mg + AmB inh. (dose N/A)	54	19 NHL 5 CML	0	N/A	N/A	N/A	N/A

For abbreviations refer to Table S1, *at 28 days, **at 24 weeks.

Table S7. Caspofungin and micafungin prophylaxis.

Author	Year	Design	Medication/daily dose per treatment arm	n=	Risk factors %	Invasive fungal infection			Mortality	
						Proven %	Probable %	Possible %	Total %	Fungal %
van Burik ⁸⁹	2004	rd, db, pl	MIC 50 mg FLU 400 mg i.v.	425	14 AML	20	26.5	N/A	4.2	0.2
				457	3 ALL 12 CML 24 NHL 20 MM 46 autoSCT 54 alloSCT					
Hashino ⁹⁶	2008	hist contr	MIC 100 mg FLU 400 p.o. OR i.v.	44	27 AML	0	0	11.4	9.1	0
				29	19 ALL 54 other 100 alloSCT	6.9	3.4	24.1	10.3	6.9
Mattiuzzi ⁸⁷	2006	rd	CAS 50 mg ITR 400 mg i.v. (d1-2), 200 mg i.v. (d3-)	107	75 AML	6.5	N/A	N/A	6.5	3.7
				90	25 MDS	5.5	N/A	N/A	7.8	2.2

For abbreviations refer to Table S1.

Additional references

45. Vehreschild JJ, Bohme A, Buchheidt D, Arenz D, Harnischmacher U, Heussel CP, et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). *J Infect* 2007;55:445-9.
116. Doellmann T, Klimasch T, Heil G, Krauter J, Elser C, Ganser A, et al. Effective prophylaxis of chronic disseminated candidiasis and pulmonary infiltrations in acute leukemia patients with intensive low-dose i.v. amphotericin B. *Jahrestagung der Deutschen Gesellschaft für Hämatologie und Onkologie*; 1999. Jena p. 505.
117. Rousey SR, Russler S, Gottlieb M, Ash RC. Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation. *Am J Med* 1991;91:484-92.
118. Riley DK, Pavia AT, Beatty PG, Petersen FB, Spruance JL, Stokes R, et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. *Am J Med* 1994; 97:509-14.
119. El-Cheikh J, Faucher C, Furst S, Duran S, Berger P, Vey N, et al. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation. *Bone Marrow Transplant* 2007;39:301-6.